Frazier William sold $117K of VMD

Frazier William (Chief Medical Officer) sold 10,000 shares of VIEMED HEALTHCARE, INC. (VMD) at $11.72 ($0.12M total) on 2026-06-25.

Original reporting
SEC EDGAR · Frazier William
Published Jun 26, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:59 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$VMD
Neutral
medium confidence
Mentioned
$VMD
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VMDNeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price, and post-transaction holdings by the Chief Medical Officer.

02

Market read

Traders may monitor VMD for follow-on insider activity, but the disclosure alone does not change the company’s fundamentals.

03

What to watch

The filing does not disclose reasons for the sale, whether other insiders sold/bought, or any concurrent operational updates that would connect the transaction to fundamentals.

Relevance 4/10Novelty 4/10Timing: filed 2026-06-26, sale dated 2026-06-25

Background

The article is an SEC Form 4 insider transaction disclosure for VIEMED Healthcare, Inc. (VMD).

Company-level read

Ticker impact

$VMDNeutralMedium confidence
Context

Form 4 shows CMO Frazier William sold 10,000 shares of VIEMED Healthcare at $11.72 on 2026-06-25, totaling $117,200.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is a primary-source Form 4, but it provides no new company performance, guidance, or deal information. Insider sales often have non-informational explanations, and the article lacks follow-on context.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity or tax-related, and the absence of a stated 10b5-1 plan does not necessarily imply negative information.

Key entities

  • VIEMED HEALTHCARE, INC.

    Subject of the Form 4 insider transaction disclosure.

  • Frazier William

    Chief Medical Officer who sold 10,000 shares.

  • SEC Form 4

    Primary-source insider transaction report filed 2026-06-26.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$VMDMedAI 8/10

Viemed Healthcare Q3 Earnings Call Highlights

VieMed Healthcare (VMD) reported Q3 operating cash flow of $11.5M and free cash flow of $4M. The company expects Q4 improvements in collections and active ventilator patients. Full-year revenue guidance was raised to $316M-$320M, while adjusted EBITDA was narrowed to $64M-$66M. VieMed had $9.7M in cash and $5.3M in borrowings at Q3's end, with a $1M share buyback and $2M term-loan repayment in October.

$VMDMed

Viemed Healthcare Inc (VMD) (Q3 2026) Earnings Call Highlights: Record Revenue

Viemed Healthcare reported Q3 2026 record revenue of $80M. CEO Casey Boyd discussed state rollout timelines, expecting gradual growth. CFO Trey Fitzgerald addressed sequential growth gaps, seasonal trends, and financial KPIs, targeting EBITDA above 20%. Accounts receivable delays impacted cash flow but are expected to resolve in Q4. Boyd also updated on sales force training, M&A pipeline, and patient education progress.

$VMDMed

VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS

VIEMED HEALTHCARE, INC. (VMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. VIEMED HEALTHCARE ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS Lafayette, Louisiana (November 4, 2026) Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD), a national provider of technology-enabled, home-based healthcare solutions and chronic disease management, an

$VMDMedAI 8/10

Viemed Healthcare Targets Low-20% Growth as Home Ventilation Opportunity Expands

Viemed Healthcare (NASDAQ: VMD) anticipates low-20% revenue growth in 2026, with projected revenue of $317M and EBITDA of $66M. The company's ventilator business averages $1,050 monthly per rental, with an average patient length of 17 months. Viemed has expanded into sleep therapy, maternal health, and other areas, completing three acquisitions in the past three years. The company has no net debt and has repurchased nearly 700,000 shares. Management sees organic growth and strategic acquisitions